The partnership between the Nashville, Tenn.-based network and the Cambridge, Mass.-based bio-information company comprises collaborative research centered on expediting molecular insights and improving patient care through clinico-genomic data.
OneOncology will use its patient data to design new approaches to clinical testing and further research efforts that address cancer treatment knowledge gaps and disparities.
“I am a big proponent of understanding the molecular landscape of a patient’s cancer in order to determine the appropriate treatment course for patients with advanced cancer over multiple lines of therapy,” OneOncology CMO Lee Schwartzberg, MD, said in an Aug. 17 news release. “We’re excited to optimize comprehensive genomic profiling, and its power to inform more personalized care across our network.”
More articles oncology:
How the pandemic will affect the future of cancer care: 3 specialists weigh in
Novant Health opens $24M cancer institute
44% of breast cancer survivors had care delays in April, survey shows
